Bezuclastinib in combination with sunitinib
SARC044
Phase 2 small_molecule active
Quick answer
Bezuclastinib in combination with sunitinib for Gastrointestinal Stromal Tumors is a Phase 2 program (small_molecule) at Cogent Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cogent Biosciences
- Indication
- Gastrointestinal Stromal Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active